List of works - A Amatu

Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization.

scientific article

Adaptive mutability of colorectal cancers in response to targeted therapies

scientific article published on 07 November 2019

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

scientific article

Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

scientific article published on July 2013

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

scientific article published on 7 July 2015

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

scientific article published in February 2014

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.

scientific article

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

scientific article

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

scientific article published on 25 June 2015

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

scientific article

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

scientific article published on 05 April 2019

Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2– Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials ⬇️

scientific article published on December 6, 2011

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

scientific article published on 30 June 2014

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

scientific article

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

scientific article

Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.

scientific article

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).

scientific article published on 5 November 2015

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

scientific article published on 01 September 2020

Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies.

scientific article published on 26 September 2015

Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.

scientific article

Regorafenib in metastatic colorectal cancer.

scientific article

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

scientific article

The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer

scientific article published on 04 January 2021

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

scientific article

Treatment of chronic hepatitis C in a patient affected by systemic sclerosis.

scientific article

Validation of an LC-MS/MS method for the determination of epirubicin in human serum of patients undergoing drug eluting microsphere-transarterial chemoembolization (DEM-TACE).

scientific article published on 19 September 2009

List of works by A Amatu

Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization.

Adaptive mutability of colorectal cancers in response to targeted therapies

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2– Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials ⬇️

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies.

Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.

Regorafenib in metastatic colorectal cancer.

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

Treatment of chronic hepatitis C in a patient affected by systemic sclerosis.

Validation of an LC-MS/MS method for the determination of epirubicin in human serum of patients undergoing drug eluting microsphere-transarterial chemoembolization (DEM-TACE).